Your guide to the increasingly complicated world of SMA

SMA, a once untreatable neuromuscular disease, will likely soon have three therapies for patients. But just which one will become the standard of care remains an open question.

This week’s American Academy of Neurology meeting offered some clues, and we dug through the new data to fill in some outstanding blanks when it comes to SMA. Is Novartis’s one-time gene therapy better than Biogen’s every-four-months injection? Can Roche’s oral treatment upend them both? When will reporters and analysts stop doing problematic cross-trial comparisons?

The answers all come with caveats, but AAN provided plenty of new evidence to inform the debate about the future of SMA.

Read more.